Strategy Inc. developed from an enterprise analytics company into a listed company with a Bitcoin-dominant treasury structure funded mainly through common equity, preferred stock, and convertible debt.The case offers an observable instance of how a concentrated crypto-asset position interacts with financial reporting, cash commitments, and shareholder exposure.The study uses a descriptive, exploratory single-case design and public evidence from Strategy's 2025 Form 10-K, its Form 10-Q for the six months ended 30 June 2026, related Form 8-K disclosures, and Accounting Standards Update 2023-08.Descriptive ratios and transparent static price scenarios connect reported accounting data with treasury decisions.Bitcoin represented 94.5% of total assets at 30 June 2026.The company recorded a $22.77 billion unrealised digital-asset loss during the first half of 2026, equal to 43.3% of period-end total assets and 1.03 times the combined $22.13 billion of long-term debt and preferred claims.Financing activities supplied $13.77 billion of cash and operating activities supplied $9.85 million, so external financing supplied 95.8% of investment cash.A reserve of $3.75 billion at 24 July 2026 covered approximately 26 months of two specified contractual commitments, preferred dividends, and interest, and not total liquidity.Static price scenarios show Bitcoin market value covering long-term debt between 5.06 and 12.65 times and the combined senior claims between 1.53 and 3.81 times at prices from $40,000 to $100,000, before taxes, transaction costs, and market impact.Common-share growth of 24.7% increased dilution, while Bitcoin per assumed diluted share rose 8.1% because holdings grew faster; that measure records gross exposure per share and not shareholder value.The study specifies a case-derived analytical framework comprising asset concentration, coverage of specified contractual commitments, financing dependence, per-share exposure, and static asset-coverage scenarios, and states five propositions for comparative testing.The framework and its scenario outputs remain unvalidated beyond this single case, do not measure financial resilience or distress probabilities, and are neither a decision tool nor a predictive model, with application elsewhere requiring firm-specific specification, calibration, and empirical validation.
No takes yet. Share an insight, caveat, or question.
Alessio Faccia (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: